Cure8 research brief
If reliable, blood biomarkers that track IBD activity could help noninvasively follow children with Crohn’s disease or ulcerative colitis. This study suggests MMP-9 and TIMP-1 change with disease course but did not show clear, consistent links with fecal-calprotectin–defined remission.
Pediatric patients and their caregivers, pediatric and adult IBD clinicians, and researchers studying IBD biomarkers.
Researchers tested blood levels of two proteins (MMP-9 and TIMP-1) at diagnosis or flare and again at 3 and 6 months, alongside routine labs and fecal calprotectin. Most patients received standard treatments during follow-up, and some were treated with anti-TNF drugs (infliximab or adalimumab).
Overall, both MMP-9 and TIMP-1 concentrations fell over the six months, and reductions were seen in children who achieved clinical remission.
However, changes in these serum markers were not clearly linked to biomarker-defined remission by fecal calprotectin, and direct comparisons of percent changes between remission vs no-remission groups were not significant for most measures. The authors describe the TIMP-1 percentage-change finding as exploratory and advise caution in interpretation.
Structured content depth: abstract. This is a single observational clinical study in a moderate-sized pediatric cohort; the authors call some comparisons exploratory. The report does not establish these markers as validated clinical tests and further confirmation in larger or independent cohorts would be needed.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study identifies specific induction exposure targets and biomarkers tied to higher chances of deep remission at 12 months in children on anti-TNF therapy, which could inform earlier dose optimization to improve...
People on biologic therapy who lose response often face choices: switch drugs or increase dose. This study shows that escalating doses of infliximab, adalimumab, or vedolizumab frequently led to clinical improvement and...
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
